Comparing Acumen Pharmaceuticals (NASDAQ:ABOS) & MiNK Therapeutics (NASDAQ:INKT)

MiNK Therapeutics (NASDAQ:INKT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

MiNK Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Earnings and Valuation

This table compares MiNK Therapeutics and Acumen Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.39)	-1.77
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.38)	-1.71

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for MiNK Therapeutics and Acumen Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	2	0	3.00
Acumen Pharmaceuticals	0	0	3	1	3.25

MiNK Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 839.31%. Acumen Pharmaceuticals has a consensus price target of $9.00, indicating a potential upside of 281.36%. Given MiNK Therapeutics’ higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Acumen Pharmaceuticals.

Profitability

This table compares MiNK Therapeutics and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-189.14%
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%

Insider and Institutional Ownership

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 19.7% of MiNK Therapeutics shares are owned by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

MiNK Therapeutics beats Acumen Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.